Russ Conroy

In the INNOVATION trial, adding Herceptin and Perjeta to chemotherapy increased toxicity in patients with HER2-positive gastric cancers.

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic colorectal cancer.

Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer.

Receiving immediate surgery was associated with a reduction in local recurrence of breast cancer in elderly patients versus delaying surgery.

Among patients with limited-stage small cell lung cancer, the benefits of consolidation Imfinzi were seen across a number of subgroups.

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free benefits in a breast cancer subset.

Patients with limited-stage small cell lung cancer saw improvements in progression-free survival and overall survival with Imfinzi versus placebo.

PolyPEPI1018 may boost the efficacy of Tecentriq in certain patients with colorectal cancer.

Blenrep, Pomalyst and dexamethasone improved progression-free survival compared to Velcade, Pomalyst and dexamethasone in patients with relapsed/refractory myeloma.

Safety data further support datopotamab deruxtecan as a new treatment option in metastatic hormone receptor–positive, HER2-negative breast cancer.

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.

Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.

Patients with HR-positive HER2-negative advanced breast cancer, including elderly patients, derived a progression-free and overall survival benefit with Kisqali plus endocrine therapy compared with placebo plus endocrine therapy.

Findings from a phase 2 trial showed improvements in relapse-free survival with an mRNA vaccine plus Keytruda compared with Keytruda alone in patients with high-risk resected melanoma.

The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.

Central nervous system progression-free survival was shown to improve with Enhertu than with alternative treatments for patients with HER2-positive metastatic breast cancer and brain metastases.

Keytruda after nephrectomy improved disease-free survival rates in patients with clear cell renal cell carcinoma regardless of disease risk or stage.

Responses to treatment with Lenvima plus Keytruda for advanced renal cell carcinoma were present regardless of PD-L1 status.

A progression-free survival benefit was observed in patients with advanced ovarian cancer including those with homologous recombination deficient-positive status who were treated with frontline chemo plus Avastin and Imfinzi followed by maintenance therapy with an Avastin regimen.

Research found that patients diagnosed with cancer during pregnancy or postpartum tended to have slightly lower five-year survival rates than those diagnosed outside of that period.